Ipamorelin
200–300 mcg · Daily or EOD
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 3 cited sources
Evidence
- Human Studies
- 8
- Animal Studies
- 20
- Clinical Status
- Research
- Confidence
- Low
- Long-Term Safety
- Limited — early-phase pharmaceutical trials only; the development program was not carried to approval
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
A selective ghrelin-receptor agonist (growth hormone-releasing peptide) that stimulates GH release with comparatively little effect on cortisol or prolactin versus older GHRPs. Some published human pharmacology data exists from its original pharmaceutical development, which was not carried through to approval.
Common Protocols
- 200–300 mcg daily or every other day, subcutaneous, often stacked with CJC-1295
Side Effects
- Injection site reaction
- Increased appetite
- Water retention
Interactions
- Combining with other GH secretagogues compounds both effect and risk
Practical Details
- Cost
- $
- Typical Vial Size
- 5 mg
- Storage
- Refrigerate after reconstitution
Key Studies & Reviews
- Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. PMID 9849822.
- Dominikowski A et al. (2026). The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis. Front Endocrinol. PMID 42395176.
- Mayfield CK et al. (2026). Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. Am J Sports Med. PMID 41476424.
Search the Research
Ipamorelin FAQ
What is the typical Ipamorelin dosage?
Commonly reported protocols: 200–300 mcg daily or every other day, subcutaneous, often stacked with CJC-1295. Our reference entry uses 200–300 mcg, Daily or EOD. These reflect protocols reported in research and user communities, not a medical recommendation — dosing should be decided with a clinician.
What are the side effects of Ipamorelin?
Reported side effects include: Injection site reaction; Increased appetite; Water retention.
Is Ipamorelin FDA approved?
Ipamorelin is not FDA approved for human use and is generally sold as a research chemical, so purity and dosing are not regulated.
How much research is there on Ipamorelin?
Our evidence profile counts roughly 8 human and 20 animal studies, with low overall confidence. Long-term safety: Limited — early-phase pharmaceutical trials only; the development program was not carried to approval.
Does Ipamorelin interact with other drugs or supplements?
Combining with other GH secretagogues compounds both effect and risk.
How do I reconstitute Ipamorelin?
A common setup is a 5 mg vial mixed with 2 mL of bacteriostatic water, which puts a 200–300 mcg dose at about 10 units on a U-100 insulin syringe. Use the reconstitution calculator with your own vial and dose to get exact numbers. Storage: Refrigerate after reconstitution.
Compare
Related compounds
Selective GH secretagogue; minimal cortisol/prolactin